Terns Pharmaceuticals (TERN) Competitors $6.55 -0.21 (-3.11%) Closing price 04:00 PM EasternExtended Trading$6.54 0.00 (-0.08%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TERN vs. BHC, OCUL, AGIO, DNLI, IDYA, TARS, IRON, HRMY, MESO, and CGONShould you be buying Terns Pharmaceuticals stock or one of its competitors? The main competitors of Terns Pharmaceuticals include Bausch Health Cos (BHC), Ocular Therapeutix (OCUL), Agios Pharmaceuticals (AGIO), Denali Therapeutics (DNLI), IDEAYA Biosciences (IDYA), Tarsus Pharmaceuticals (TARS), Disc Medicine (IRON), Harmony Biosciences (HRMY), Mesoblast (MESO), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Terns Pharmaceuticals vs. Its Competitors Bausch Health Cos Ocular Therapeutix Agios Pharmaceuticals Denali Therapeutics IDEAYA Biosciences Tarsus Pharmaceuticals Disc Medicine Harmony Biosciences Mesoblast CG Oncology Bausch Health Cos (NYSE:BHC) and Terns Pharmaceuticals (NASDAQ:TERN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership. Which has more risk & volatility, BHC or TERN? Bausch Health Cos has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.05, suggesting that its share price is 105% less volatile than the S&P 500. Is BHC or TERN more profitable? Bausch Health Cos has a net margin of 0.99% compared to Terns Pharmaceuticals' net margin of 0.00%. Terns Pharmaceuticals' return on equity of -27.35% beat Bausch Health Cos' return on equity.Company Net Margins Return on Equity Return on Assets Bausch Health Cos0.99% -852.36% 5.25% Terns Pharmaceuticals N/A -27.35%-26.18% Does the media refer more to BHC or TERN? In the previous week, Bausch Health Cos had 19 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 19 mentions for Bausch Health Cos and 0 mentions for Terns Pharmaceuticals. Bausch Health Cos' average media sentiment score of 0.99 beat Terns Pharmaceuticals' score of 0.31 indicating that Bausch Health Cos is being referred to more favorably in the media. Company Overall Sentiment Bausch Health Cos Positive Terns Pharmaceuticals Neutral Which has better valuation and earnings, BHC or TERN? Bausch Health Cos has higher revenue and earnings than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBausch Health Cos$9.86B0.29-$46M$0.2629.98Terns PharmaceuticalsN/AN/A-$88.85M-$1.04-6.30 Do insiders & institutionals hold more shares of BHC or TERN? 78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are owned by institutional investors. 8.1% of Bausch Health Cos shares are owned by company insiders. Comparatively, 1.5% of Terns Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts recommend BHC or TERN? Bausch Health Cos currently has a consensus target price of $9.00, suggesting a potential upside of 15.46%. Terns Pharmaceuticals has a consensus target price of $15.63, suggesting a potential upside of 138.55%. Given Terns Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Terns Pharmaceuticals is more favorable than Bausch Health Cos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Cos 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummaryBausch Health Cos beats Terns Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TERN vs. The Competition Export to ExcelMetricTerns PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$573.19M$3.07B$5.76B$9.65BDividend YieldN/A2.22%3.91%4.09%P/E Ratio-6.3020.4830.7825.12Price / SalesN/A355.18456.64116.46Price / CashN/A41.5625.2228.45Price / Book1.619.549.375.95Net Income-$88.85M-$54.74M$3.26B$265.46M7 Day Performance0.31%2.39%1.88%0.96%1 Month Performance16.13%4.60%3.73%2.47%1 Year Performance-18.13%9.17%28.93%20.24% Terns Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TERNTerns Pharmaceuticals3.9148 of 5 stars$6.55-3.1%$15.63+138.5%-6.8%$573.19MN/A-6.3040Positive NewsBHCBausch Health Cos4.3014 of 5 stars$6.68+16.1%$9.00+34.8%+40.0%$2.13B$9.63B25.6820,700High Trading VolumeOCULOcular Therapeutix4.0481 of 5 stars$12.56+2.9%$17.20+36.9%+51.8%$2.12B$63.72M-9.81230AGIOAgios Pharmaceuticals4.2053 of 5 stars$35.10-1.8%$56.33+60.5%-16.8%$2.08B$36.50M3.19390DNLIDenali Therapeutics4.1274 of 5 stars$13.91-0.3%$33.85+143.3%-35.6%$2.03B$330.53M-5.21430Analyst ForecastAnalyst RevisionIDYAIDEAYA Biosciences4.4713 of 5 stars$22.84-1.1%$48.09+110.6%-34.5%$2.02B$7M-6.0380TARSTarsus Pharmaceuticals1.9716 of 5 stars$50.07+4.6%$66.67+33.1%+112.6%$2.02B$182.95M-21.4950IRONDisc Medicine3.6258 of 5 stars$58.59+1.0%$95.73+63.4%+22.7%$2.01BN/A-13.1130Analyst ForecastHRMYHarmony Biosciences4.5907 of 5 stars$34.80+1.8%$51.00+46.6%+4.2%$1.97B$714.73M11.23200MESOMesoblast1.901 of 5 stars$14.70-2.2%$18.00+22.4%+139.2%$1.92B$5.90M0.0080Gap DownCGONCG Oncology1.3724 of 5 stars$23.94-3.7%$55.30+131.0%-23.6%$1.89B$1.14M-13.5361Analyst Forecast Related Companies and Tools Related Companies Bausch Health Cos Competitors Ocular Therapeutix Competitors Agios Pharmaceuticals Competitors Denali Therapeutics Competitors IDEAYA Biosciences Competitors Tarsus Pharmaceuticals Competitors Disc Medicine Competitors Harmony Biosciences Competitors Mesoblast Competitors CG Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TERN) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access